Browse studies, page 1083
Page 1083 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020
- Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge Frontiers in medicine, 2021
- Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs American journal of cardiovascular drugs : drugs, devices, and other interventions, 2017
- Cardioprotective anti-hyperglycaemic medications: a review of clinical trials European heart journal, 2018
- Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review Journal of the American College of Cardiology, 2018
- Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives Antioxidants (Basel, Switzerland), 2024
- Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress Current atherosclerosis reports, 2021
- Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis International urology and nephrology, 2022
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 European Society of Cardiology Congress Current atherosclerosis reports, 2022
- Resolving the KgA1c paradox in the management of type 2 diabetes mellitus Diabetes & metabolic syndrome, 2017
- Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis JACC. Basic to translational science, 2026
- SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy Drug design, development and therapy, 2020
- Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives Current pharmaceutical design, 2014
- Cardiovascular Outcome Trials with Glucose-Lowering Drugs Current cardiology reports, 2021
- Lupus Nephritis: New and Emerging Biologic and Targeted Therapies BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2023
- The Role of SGLT2 Inhibitors in Atherosclerosis: A Systematic Review Journal of community hospital internal medicine perspectives, 2025
- Role of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors in Preventing Cardiac Surgery-Associated Acute Kidney Injury: A Scoping Review Cureus, 2025
- A clever evaluation of the antidiabetic medications linagliptin and empagliflozin in bulk and spiked urine samples Bioanalysis, 2025
- The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review Cureus, 2023
- Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure ESC heart failure, 2022
- Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician International journal of clinical practice, 2017
- Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies The American journal of medicine, 2017
- Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus Clinical pharmacokinetics, 2014
- Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs International journal of cardiology. Heart & vasculature, 2018
- SGLT2 inhibition and heart failure-current concepts Heart failure reviews, 2018
- The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies Clinical pharmacology : advances and applications, 2016
- SGLT2 Inhibitors and Mechanisms of Hypertension Current cardiology reports, 2018
- SGLT2 inhibitors in heart failure with reduced ejection fraction The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2021
- Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure Wiadomosci lekarskie (Warsaw, Poland : 1960), 2024
- Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus Cureus, 2017
- Improvement of renal outcomes with sodium-glucose cotransporter-2 (SGLT2) inhibitors Harefuah, 2021
- Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction ESC heart failure, 2022
- Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions Current diabetes reports, 2017
- Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2026
- Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence European heart journal. Cardiovascular pharmacotherapy, 2022
- Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors: Insight to uncommon cardiovascular disease scenarios in diabetes World journal of diabetes, 2024
- Exploring SGLT2 Inhibitors' Activity in Breast Cancer: An Overview Current topics in medicinal chemistry, 2025
- Neuroprotective Effect of SGLT2 Inhibitors Molecules (Basel, Switzerland), 2021
- Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes Cardiac failure review, 2019
- Targeting NLRP3 Inflammasomes in Myocarditis: Potential Therapeutic Strategies and Clinical Translation Scientifica, 2026
- Dapagliflozin and DAPA‐HF: from glycaemic control to heart failure therapy Practical diabetes, 2019
- Sodium–glucose co‐transporter 2 inhibitors: strength of evidence for a cardio‐renal‐metabolic therapy European Journal of Heart Failure, 2021
- Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure Heart, 2021
- Dissolution or disintegration – substitution of dissolution by disintegration testing for a fixed dose combination product Drug Development and Industrial Pharmacy, 2018
- Renal function and vericiguat in heart failure patients: light at the end of the tunnel! European Journal of Heart Failure, 2021
- Abstract 15820: The Use of Sglt 2 Inhibitors During Hospitalization for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis Circulation, 2022
- 21-OR: Optimization of Albuminuria Lowering Treatment by Crossover Rotation to Four Different Drug Classes Diabetes, 2022
- Innovative TLC-densitometric method with fluorescent detection for simultaneous determination of ternary anti-diabetic mixture in pharmaceutical formulations and human plasma 2021
- The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction Therapeutic Advances in Cardiovascular Disease, 2021
- Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective ESC Heart Failure, 2020
- Abstract P3149: Effect Of SGLT2 Inhibitors On Atrial Fibrillation Susceptibility In Diabetic Mice Circulation Research, 2023
- Evaluation of Inpatient Sodium-Glucose Co-Transporter-2 Inhibitor Use in Patients Hospitalized for Acute Heart Failure American Journal of Cardiology, 2023
- Advances in contemporary medical management to treat patients with heart failure Current Opinion in Cardiology, 2023
- 8494 A Case of Diabetic Ketoacidosis in Setting of COVID-19 Infection and SGLT-2 Inhibitor Use Journal of the Endocrine Society, 2024
- SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects? Cardiology in Review, 2024
- Guidelines for Treating Heart Failure Trends in cardiovascular medicine, 2024
- ВПЛИВ ДОДАВАННЯ ЕМПАГЛІФЛОЗИНУ ДО СТАНДАРТНОЇ ТЕРАПІЇ НА ЕХОКАРДІОГРАФІЧНІ ПОКАЗНИКИ ТА БІОМАРКЕРИ У ПАЦІЄНТІВ З ІНФАРКТОМ МІОКАРДА ТА ЗНИЖЕНОЮ ФРАКЦІЄЮ ВИКИДУ ЛІВОГО ШЛУНОЧКА Art of medicine, 2026
- Safety and Short-Term Cardiorenal Effects of Initiating SGLT2 Inhibitors During Ramadan Fasting in Non-Diabetic Patients With Heart Failure With Reduced Ejection Fraction Pakistan Heart Journal, 2026
- Sodium glucose transporter 2 inhibitors for heart failure World Journal of Cardiology, 2026
- Effects of SGLT2 Inhibition on Cardiac Structure, Left Atrial Function, and Fibrotic Biomarkers in HFpEF with Type 2 Diabetes Bratislava Medical Journal, 2026
- Short-Term Efficacy of Early Sodium–Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure After Acute Anterior Myocardial Infarction Reviews in cardiovascular medicine, 2026
- Adoption and diffusion of SGLT2 inhibitors among cardiologists in medicare part D, 2019–2023: a provider-level observational study BMC Cardiovascular Disorders, 2026
- Safety of early and accelerated evidence based pharmacological therapy following acute decompensated heart failure (the fil–ahf study) European Heart Journal, Supplement, 2026
- Medical treatment implementation in ambulatory patients with HF: preliminary data from the nationwide BRING–UP3 HF study European Heart Journal, Supplement, 2025
- SGLT2 inhibitor therapy in patients with acute Takotsubo syndrome European Heart Journal, 2025
- Discharge medical treatment implementation in patients admitted for AHF: preliminary data from the BRING–UP3 HF study European Heart Journal, Supplement, 2025
- Real-world outcomes and safety of low- vs. standard-dose SGLT2 inhibitors in heart failure European Heart Journal, 2025
- SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy—A Prospective Observational Cohort Trial Biomedicines, 2025
- CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum Cardiovascular Diabetology, 2026
- Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review) Molecular Medicine Reports, 2024
- Medical treatments in ambulatory heart failure patients: First data from the BRING-UP-3 Heart Failure Study Journal of Cardiac Failure, 2025
- SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting European Heart Journal, Supplement, 2025
- SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health Kidney Medicine, 2024
- Effects of Empagliflozin on Extracellular Volume, Plasma Volume, and Measured Glomerular Filtration Rate in Patients with Heart Failure: A Double-Blind, Randomised, and Placebo-Controlled Trial (Empire HF Renal) 2021
- Management of chronic heart failure: state of the art according to the 2021 guideline Innere Medizin, 2022
- Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic European Journal of Heart Failure, 2020
- Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction Journal of the American College of Cardiology, 2020
- Abstract 14084: Empagliflozin in Hospitalized Patients With Heart Failure Circulation, 2023
- The implementation of modern guideline-directed medical therapy among hospitalized patients with heart failure with reduced ejection fraction: real-world experience from two tertiary cardiac centers European Heart Journal, 2024
- Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States Clinical Therapeutics, 2023
- The National Financial Burden of Guideline Directed Medical Therapy for Heart Failure Patients from 2013 to 2021 Current problems in cardiology, 2024
- Early empagliflozin initiation after hospitalization for heart failure in the United States: a target trial emulation European Journal of Heart Failure, 2026
- Evaluating the budget impact of Empagliflozin in managing heart failure with reduced ejection fraction: Proposing strategic policies for Malaysian public healthcare PLoS ONE, 2024
- Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes 2016
- Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: lessons from preclinical studies Chemico-Biological Interactions, 2024
- Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial Cardiovascular Diabetology, 2023
- Abstract 4373610: Effect of combined guideline-directed medical therapy and mitochondria-rich extracellular vesicles in a mouse infarct model Circulation, 2025
- Effects of early empagliflozin in acute decompensated HFrEF on ventricular systolic and diastolic parameters: interaction with endothelial function and arterial stiffness European Heart Journal, 2025
- Early Efficacy of Empagliflozin in Addition to Optimal Medical Treatment of Heart Failure with Reduced Ejection Fraction Cardiology and Cardiovascular Research, 2025
- Development and Validation of New Analytical Method for the Determination of Particle Size Distribution in Empagliflozin Using Laser-Based Particle Size Analyzer Journal of Advances in Medical and Pharmaceutical Sciences, 2025
- Spanish Adaptation of the 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice Revista espanola de salud publica, 2016
- Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease Gastroenterology, 2021
- Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline The Journal of clinical endocrinology and metabolism, 2019
- Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association The Korean journal of internal medicine, 2017
- Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes Canadian family physician Medecin de famille canadien, 2019
- Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association Circulation, 2020
- Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021 BMC nephrology, 2022
- Guidelines for the management of diabetes in care homes during the Covid-19 pandemic Diabetic medicine : a journal of the British Diabetic Association, 2020
- Mexican position paper for the diagnosis and treatment of cardiac amyloidosis Archivos de cardiologia de Mexico, 2024
- Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology Journal of the American College of Cardiology, 2023
